Not yet recruiting
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
NCT07788469· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Wei Liu
Not yet recruiting
A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
NCT07789587· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Wei Liu
Recruiting
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT07362238· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Lei Zhang, MD
Recruiting
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Lei Zhang, MD
Recruiting
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Lei Zhang, MD
Recruiting
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Lei Zhang, MD
Recruiting
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Ting Sun, MD
Recruiting
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
NCT06992128· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yunfei Chen
Recruiting
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
NCT06838949· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yunfei Chen
Recruiting
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
NCT06799611· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yunfei Chen, MD
Recruiting
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
NCT06776510· Phase 1/2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yunfei Chen, MD
Recruiting
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Ting Sun, MD
Active, not recruiting
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
NCT06199089· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Recruiting
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Ting Sun, MD
Recruiting
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Ting Sun, MD
Recruiting
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
NCT05849740· Phase 4· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Shuo Chen
Recruiting
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NCT05214391· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yunfei Chen, MD
Recruiting
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia
NCT05199909· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Yunfei Chen, MD
Recruiting
Gene Therapy for Chinese Hemophilia A
NCT04728841· Institute of Hematology & Blood Diseases Hospital, China· Source
Contact: Shuo Chen, MD